Lucius Sotorasib – Buy online
Sotorazib is a prescription drug that targets the KRAS G12C mutant protein. It received accelerated approval from the U.S. FDA on May 28, 2021. Patients should use it only as directed by their doctor.
View Product
CodeBreaK 101 at ASCO 2025: Sotorasib Triplet in KRAS CRC – Oncodaily
CodeBreaK 101 at ASCO 2025: Sotorasib Triple Therapy for KRAS CRC (Oncodaily)
Full Article Content
ASCO 2025: CodeBreaK 101 shows sotorasib triplet therapy offers durable responses in KRAS G12C-mutant metastatic colorectal cancer. , ASCO 2025 Annual Meeting, CodeBreaK 101 trial, colorectal cancer, KRASG12C
Products Mentioned in This Article
These products were automatically matched from the article title, summary, and full content.
SOTOLDX Sotorasib 120mg
On May 29, 2021, the U.S. FDA announced accelerated approval for sotorasib (AMG510) for the treatment of patients with non-small cell lung cancer (NSCLC) harboring KRAS G12C mutations. These patients had received at least one prior systemic therapy. This is the world's first anticancer therapy targeting a specific KRAS gene mutation.
View Product
Frequently Asked Questions
Which products are related to this article?
The system matched these relevant products from the article content: Lucius Sotorasib – Buy online、SOTOLDX Sotorasib 120mg.
How can I view the medicines discussed in this article?
Use the related product cards below the article to review available specifications, prices, product information, and reviews.
Does this article replace advice from a doctor or pharmacist?
No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.
